On August 5, 2026, AVITA Medical entered into a Global Amendment with Stedical Scientific to expand its exclusive distribution rights and adjust revenue sharing terms. In exchange for a $500,000 fee, the Company secured rights of first offer and refusal to expand territory into the European Union, United Kingdom, and Australia. Revenue shares from PermeaDerm sales increased to 67% for sheet form products and 80% for glove form products, subject to margin-based adjustments. The amendment imposes a $1.0 million revenue sharing payment requirement for 2026 with 20% annual growth through 2030, while waiving previous minimums. Stedical may also commercialize PermeaDerm in certain U.S. markets and Asia under specific manufacturing cost-plus pricing structures. AVITA Medical operates in the medical device industry, specializing in regenerative medicine products for wound care.

AVITA Medical reported second quarter 2026 net revenue of $21.7 million, an 18% year-over-year increase and a record high, driven by RECELL sales of $18.5 million. The company raised its full-year 2026 revenue guidance to $86–$89 million from the previous range of $80–$85 million and expects to reach cash flow breakeven in the fourth quarter of 2026. Operating expenses decreased 6% year-over-year to $24.6 million, while net loss narrowed to $7.7 million ($0.25 per share) from $9.9 million in the prior-year period. The Centers for Medicare & Medicaid Services proposed national physician payment rates and increased facility payments for RECELL effective January 1, 2027. AVITA Medical operates in the therapeutic acute wound care industry, developing and commercializing solutions such as RECELL spray-on skin technology.

AVITA Medical, Inc. issued a warrant certificate to Perceptive Credit Holdings V, LP on June 5, 2026, following stockholder approval at the 2026 Annual Meeting. The warrant allows Perceptive to purchase up to 500,000 shares of common stock at an exercise price of $3.4019 per share, with a potential additional 150,000 shares if a certain net revenue requirement is met.